Ningbo Kunpeng Biotech Co., Ltd. was established in April 2016. The company takes "providing medicines, technologies and services for human disease control" as its mission and is committed to the research, development, production and sales of human drugs. In the field of diabetes treatment drugs, the company has developed a product including recombinant human insulin, insulin glargine, insulin aspart, liraglutide and other pharmaceutical products using the unique "protein fixed-point modification technology" platform and subversive process engineering technology development. chain. At the same time, research on new drugs such as new long-acting insulin and GLP-1 analogs is also actively underway. The company has a complete R&D and pilot test platform, and has formed a team of R&D, production and quality management talents including several domestic and foreign technical experts. In the first phase of industrialization, RMB 200 million Details>>
Graduation season | Youth is just right, "job"
Graduation season | Youth is just right, "job" is for you
[Good news] Kunpeng successfully bid......
Kunpeng Bio has actively participated in the auction of state-owned industrial land. As of September 19, 2019, it had successfully auctioned Kundi.com's "2019" Gongzai No. 35, the east side of Gucheng Road
Annual Meeting 丨 Building the future......
Kunpeng Biological Annual Meeting 2019 January 03, 2020 Kunpeng Bio's 2019 annual conference has quietly kicked off 2019 is a year worth remembering This year, every day of Kun Peng is changing and moving forward.
Epidemic prevention and control resumed ......
Epidemic prevention and control has entered a new stage, and the tide of resumption of work and production is approaching. In the more than half a month
Copyright© 2019 Copyright © 2012 kunpeng biotechnology co., LTD. All rights reserved